
Releases
Lilly’s Jaypirca combination cuts disease progression risk in CLL by 45%
Adding Eli Lilly’s pirtobrutinib to a standard venetoclax and rituximab regimen significantly improved outcomes for patients with relapsed or refractory chronic lymphocytic leukemia, according to results from the Phase 3 BRUIN CLL-322 trial presented ahead of the 2026 European Hematology Association Annual Meeting.




















